Latest Mapatumumab Stories
Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.
ROCKVILLE, Md., July 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
- Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr.
- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer - - Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment - - Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could...
Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc.
HOUSTON, May 19 /PRNewswire/ -- Agennix announced today that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent(R) - Pfizer).
Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc.
SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
-Preliminary Data from This Trial to be Presented at ASCO- -First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment- TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
- Updated Data from Initial Cohort Shows Nine of 14 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Underway in Expansion Stage of Trial with Target of Enrolling 46 Patients Overall - TUSTIN, Calif., April 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
- A hairdresser.